{{medical}}
'''癌症标志物'''（{{lang-en|Cancer biomarkers}}）是指由肿瘤细胞直接产生或由非肿瘤细胞经肿瘤细胞诱导产生的物质。对于肿瘤标志物的检测可对肿瘤存在、发病过程及预后作出判断。

癌症标志物可回答的问题：
* 预后：这种癌症可能继续生长？
* 诊断：我患了何种癌症？
* 预测：这种药是针对我患肿瘤的最佳用药吗？
* 药效学：对我来说此药的最佳用量是多少？
* 复发：肿瘤会再次发作吗？

== 癌症标志物的种类 ==
===分子癌症标志物===
{| border="1"| class="wikitable"
|-
! '''肿瘤类型''' !! '''生物标志物'''
|-
|rowspan="2" | 乳腺
| ER（雌激素受体）<ref name="table">{{cite web |title=Table of Pharmacogenomic Biomarkers in Drug Labels |url=http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm. |publisher=U.S Food and Drug Administration}}</ref><ref name="two">{{cite web |title=Tumor Markers Fact Sheet |url=http://www.cancer.org/acs/groups/cid/documents/webcontent/003189-pdf.pdf |publisher=American Cancer Society |format=PDF}}</ref> 
|-
| HER-2/neu<ref name="table"/><ref name="two"/>
|-
|rowspan="3" |结直肠
| EGFR<ref name="table"/><ref name="two"/>
|-
| KRAS<ref name="table"/><ref name="three">{{cite web |last=Lenz |first=Heinz-Josef |title=Established Biomarkers in Colon Cancer |url=http://www.asco.org/ASCOv2/Home/Education%20&%20Training/Educational%20Book/PDF%20Files/2009/09 EdBk.GI.Colo.04.pdf |publisher=American Society of Clinical Oncology’s 2009 Educational Book |format=PDF }}{{dead link|date=2018年3月 |bot=InternetArchiveBot |fix-attempted=yes }}</ref> 
|-
| UGT1A1<ref name="table"/><ref name="three"/>
|-
|胃
| HER-2/neu<ref name="table"/>
|-
|胃腸道基質腫瘤
| c-KIT<ref name="table"/><ref>{{cite journal |author=Gonzalez RS, Carlson G, Page AJ, Cohen C |title=Gastrointestinal stromal tumor markers in cutaneous melanomas: relationship to prognostic factors and outcome |journal=Am. J. Clin. Pathol. |volume=136 |issue=1 |pages=74–80 |pmid=21685034 |doi=10.1309/AJCP9KHD7DCHWLMO |date=July 2011}}</ref> 
|-
|rowspan="8" |白血病/淋巴瘤
|CD20抗原<ref name="table"/><ref>{{cite journal |author=Tam CS, Otero-Palacios J, Abruzzo LV, ''et al.'' |title=Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients |journal=Br. J. Haematol. |volume=141 |issue=1 |pages=36–40 |pmid=18324964 |doi=10.1111/j.1365-2141.2008.07012.x |date=April 2008}}</ref> 
|-
|CD30<ref name="table"/><ref>{{cite journal |author=Zhang M, Yao Z, Patel H, ''et al.'' |title=Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1 |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=104 |issue=20 |pages=8444–8 |pmid=17488826 |pmc=1895969 |doi=10.1073/pnas.0702496104 |url=http://www.pnas.org/cgi/pmidlookup?view=long&pmid=17488826|date=May 2007}}</ref> 
|-
|FIP1L1-PDGRFα<ref name="table"/><ref>{{cite journal |author=Yamada Y, Sanchez-Aguilera A, Brandt EB, ''et al.'' |title=FIP1L1/PDGFRalpha synergizes with SCF to induce systemic mastocytosis in a murine model of chronic eosinophilic leukemia/hypereosinophilic syndrome |journal=Blood |volume=112 |issue=6 |pages=2500–7 |pmid=18539901 |doi=10.1182/blood-2007-11-126268 |url=http://bloodjournal.hematologylibrary.org/cgi/pmidlookup?view=long&pmid=18539901|date=September 2008}}</ref> 
|-
|PDGFR<ref name="table"/><ref>{{cite journal |author=Nimer SD |title=Myelodysplastic syndromes |journal=Blood |volume=111 |issue=10 |pages=4841–51 |pmid=18467609 |doi=10.1182/blood-2007-08-078139 |url=http://bloodjournal.hematologylibrary.org/cgi/pmidlookup?view=long&pmid=18467609|date=May 2008}}</ref> 
|-
|费城染色体（BCR/ABL）<ref name="table"/><ref>{{cite journal |author=Ottmann O, Dombret H, Martinelli G, ''et al.'' |title=Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study |journal=Blood |volume=110 |issue=7 |pages=2309–15 |pmid=17496201 |doi=10.1182/blood-2007-02-073528 |url=http://bloodjournal.hematologylibrary.org/cgi/pmidlookup?view=long&pmid=17496201|date=October 2007}}</ref><ref>{{cite journal |author=Boulos N, Mulder HL, Calabrese CR, ''et al.'' |title=Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia |journal=Blood |volume=117 |issue=13 |pages=3585–95 |pmid=21263154 |pmc=3072880 |doi=10.1182/blood-2010-08-301267 |url=http://bloodjournal.hematologylibrary.org/cgi/pmidlookup?view=long&pmid=21263154|date=March 2011}}</ref> 
|-
|PML/RARα<ref name="table"/><ref>{{cite journal |author=O'Connell PA, Madureira PA, Berman JN, Liwski RS, Waisman DM |title=Regulation of S100A10 by the PML-RAR-α oncoprotein |journal=Blood |volume=117 |issue=15 |pages=4095–105 |pmid=21310922 |doi=10.1182/blood-2010-07-298851 |url=http://bloodjournal.hematologylibrary.org/cgi/pmidlookup?view=long&pmid=21310922|date=April 2011}}</ref> 
|-
|TPMT<ref name="table"/><ref>{{cite journal |author=Duffy MJ, Crown J |title=A personalized approach to cancer treatment: how biomarkers can help |journal=Clin. Chem. |volume=54 |issue=11 |pages=1770–9 |pmid=18801934 |doi=10.1373/clinchem.2008.110056 |url=http://www.clinchem.org/cgi/pmidlookup?view=long&pmid=18801934|date=November 2008}}</ref> 
|-
|UGT1A1<ref name="table"/><ref>{{cite journal |author=Ribrag V, Koscielny S, Casasnovas O, ''et al.'' |title=Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis |journal=Blood |volume=113 |issue=14 |pages=3307–13 |pmid=18768784 |doi=10.1182/blood-2008-03-148874 |url=http://bloodjournal.hematologylibrary.org/cgi/pmidlookup?view=long&pmid=18768784|date=April 2009}}</ref> 
|-
|rowspan="3" | 肺
|ALK<ref name="table"/><ref>{{cite journal |author=Li Y, Ye X, Liu J, Zha J, Pei L |title=Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors |journal=Neoplasia |volume=13 |issue=1 |pages=1–11 |pmid=21245935 |pmc=3022423 |url=http://www.neoplasia.com/abstract.php?msid=3835 |date=January 2011 }}{{dead link|date=2018年1月 |bot=InternetArchiveBot |fix-attempted=yes }}</ref><ref name="lo">{{cite journal |author=Pao W, Girard N |title=New driver mutations in non-small-cell lung cancer |journal=Lancet Oncol. |volume=12 |issue=2 |pages=175–80 |pmid=21277552 |doi=10.1016/S1470-2045(10)70087-5 |url=http://linkinghub.elsevier.com/retrieve/pii/S1470-2045(10)70087-5|date=February 2011}}</ref> 
|-
|EGFR<ref name="table"/><ref name="two"/>
|-
|KRAS<ref name="table"/><ref name="two"/>
|-
|黑色素瘤
|BRAF<ref name="table"/><ref name="lo"/>
|}

生物标志物的其它例子：
*在癌症中抑癌基因表达缺失
**例子：[[BRCA1|BRCA1]]、[[BRCA2|BRCA2]]
*RNA
**例子：[[mRNA|mRNA]]、[[微RNA|微RNA]] <ref>{{cite journal |author=Bartels CL, Tsongalis GJ |title=MicroRNAs: novel biomarkers for human cancer |journal=Clin. Chem. |volume=55 |issue=4 |pages=623–31 |pmid=19246618 |doi=10.1373/clinchem.2008.112805 |url=http://www.clinchem.org/cgi/pmidlookup?view=long&pmid=19246618|date=April 2009}}</ref>
*存在于体液或组织中的蛋白质。
**例子：[[前列腺特异性抗原|前列腺特异性抗原]]和[[CA-125|CA-125]]

==参考文献==
{{reflist}}

[[Category:肿瘤学|Category:肿瘤学]]